S&P 500   3,266.76 (+0.62%)
DOW   26,917.62 (+0.38%)
QQQ   267.45 (+0.78%)
AAPL   110.76 (+2.35%)
MSFT   206.39 (+1.57%)
FB   250.60 (+0.43%)
GOOGL   1,423.94 (+0.08%)
AMZN   3,050.00 (+1.00%)
TSLA   407.30 (+5.03%)
NVDA   504.58 (+2.16%)
BABA   268.06 (-0.62%)
CGC   13.95 (-2.24%)
GE   6.05 (-0.17%)
MU   48.44 (-2.08%)
AMD   76.69 (+1.15%)
T   27.81 (-0.82%)
F   6.58 (-1.20%)
ACB   4.99 (-4.04%)
GILD   61.99 (-0.42%)
NFLX   475.42 (+0.49%)
DIS   122.23 (-0.21%)
BAC   23.20 (-0.60%)
BA   150.68 (+3.17%)
S&P 500   3,266.76 (+0.62%)
DOW   26,917.62 (+0.38%)
QQQ   267.45 (+0.78%)
AAPL   110.76 (+2.35%)
MSFT   206.39 (+1.57%)
FB   250.60 (+0.43%)
GOOGL   1,423.94 (+0.08%)
AMZN   3,050.00 (+1.00%)
TSLA   407.30 (+5.03%)
NVDA   504.58 (+2.16%)
BABA   268.06 (-0.62%)
CGC   13.95 (-2.24%)
GE   6.05 (-0.17%)
MU   48.44 (-2.08%)
AMD   76.69 (+1.15%)
T   27.81 (-0.82%)
F   6.58 (-1.20%)
ACB   4.99 (-4.04%)
GILD   61.99 (-0.42%)
NFLX   475.42 (+0.49%)
DIS   122.23 (-0.21%)
BAC   23.20 (-0.60%)
BA   150.68 (+3.17%)
S&P 500   3,266.76 (+0.62%)
DOW   26,917.62 (+0.38%)
QQQ   267.45 (+0.78%)
AAPL   110.76 (+2.35%)
MSFT   206.39 (+1.57%)
FB   250.60 (+0.43%)
GOOGL   1,423.94 (+0.08%)
AMZN   3,050.00 (+1.00%)
TSLA   407.30 (+5.03%)
NVDA   504.58 (+2.16%)
BABA   268.06 (-0.62%)
CGC   13.95 (-2.24%)
GE   6.05 (-0.17%)
MU   48.44 (-2.08%)
AMD   76.69 (+1.15%)
T   27.81 (-0.82%)
F   6.58 (-1.20%)
ACB   4.99 (-4.04%)
GILD   61.99 (-0.42%)
NFLX   475.42 (+0.49%)
DIS   122.23 (-0.21%)
BAC   23.20 (-0.60%)
BA   150.68 (+3.17%)
S&P 500   3,266.76 (+0.62%)
DOW   26,917.62 (+0.38%)
QQQ   267.45 (+0.78%)
AAPL   110.76 (+2.35%)
MSFT   206.39 (+1.57%)
FB   250.60 (+0.43%)
GOOGL   1,423.94 (+0.08%)
AMZN   3,050.00 (+1.00%)
TSLA   407.30 (+5.03%)
NVDA   504.58 (+2.16%)
BABA   268.06 (-0.62%)
CGC   13.95 (-2.24%)
GE   6.05 (-0.17%)
MU   48.44 (-2.08%)
AMD   76.69 (+1.15%)
T   27.81 (-0.82%)
F   6.58 (-1.20%)
ACB   4.99 (-4.04%)
GILD   61.99 (-0.42%)
NFLX   475.42 (+0.49%)
DIS   122.23 (-0.21%)
BAC   23.20 (-0.60%)
BA   150.68 (+3.17%)
Log in
NYSE:BNR

Legend Biotech Stock Forecast, Price & News

$21.48
+0.79 (+3.82 %)
(As of 09/25/2020 11:10 AM ET)
Add
Compare
Today's Range
$20.89
Now: $21.48
$21.48
50-Day Range
$19.07
MA: $21.72
$24.33
52-Week Range
$18.64
Now: $21.48
$32.40
Volume1,803 shs
Average Volume195,859 shs
Market Capitalization$2.19 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Burning Rock Biotech develops solutions for precision medicine in oncology and early cancer detection in the People's Republic of China. The company provides companion diagnostics for targeted therapy and immunotherapy, benign/malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests. It also offers liquid biopsy; OncoScreen Plus, a test for therapy and immunotherapy; LungPlasma, a test for non-small cell lung cancer, including various genes that have a targeted therapy; ColonCore for testing gastrointestinal cancers; and HRDCore for testing genes associated with homologous recombination deficiency. Burning Rock Biotech was founded in 2014 and is headquartered in Guangzhou, China.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone86 20 3403 7871

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees753
Market Cap$2.19 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$21.48
+0.79 (+3.82 %)
(As of 09/25/2020 11:10 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BNR News and Ratings via Email

Sign-up to receive the latest news and ratings for BNR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Legend Biotech (NYSE:BNR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Legend Biotech?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Legend Biotech
.

When is Legend Biotech's next earnings date?

Legend Biotech is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Legend Biotech
.

How were Legend Biotech's earnings last quarter?

Legend Biotech Corporation (NYSE:BNR) released its earnings results on Tuesday, August, 11th. The company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.18. The firm earned $15.14 million during the quarter.
View Legend Biotech's earnings history
.

What guidance has Legend Biotech issued on next quarter's earnings?

Legend Biotech issued an update on its FY 2020 Pre-Market earnings guidance on Tuesday, August, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $59.4-59.4 million, compared to the consensus revenue estimate of $59.44 million.

What price target have analysts set for BNR?

3 Wall Street analysts have issued 12-month price targets for Legend Biotech's stock. Their forecasts range from $32.30 to $32.30. On average, they anticipate Legend Biotech's share price to reach $32.30 in the next year. This suggests a possible upside of 50.4% from the stock's current price.
View analysts' price targets for Legend Biotech
.

Who are some of Legend Biotech's key competitors?

What other stocks do shareholders of Legend Biotech own?

Who are Legend Biotech's key executives?

Legend Biotech's management team includes the following people:
  • Mr. Yusheng Han, Founder, Chairman & CEO (Age 42)
  • Mr. Jinxiang Li, CFO, Principal Accounting Officer, Compliance Officer & Director (Age 35)
  • Dr. Shaokun Chuai, COO & Director (Age 41)
  • Dr. Zhihong Zhang, Chief Technology Officer (Age 44)
  • Mr. Hao Liu, Chief Medical Officer (Age 46)

When did Legend Biotech IPO?

(BNR) raised $196 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 13,500,000 shares at a price of $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen acted as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers.

What is Legend Biotech's stock symbol?

Legend Biotech trades on the New York Stock Exchange (NYSE) under the ticker symbol "BNR."

When does Legend Biotech's lock-up period expire?

Legend Biotech's lock-up period expires on Wednesday, December 9th. Legend Biotech had issued 13,500,000 shares in its initial public offering on June 12th. The total size of the offering was $222,750,000 based on an initial share price of $16.50. After the end of Legend Biotech's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

How do I buy shares of Legend Biotech?

Shares of BNR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Legend Biotech's stock price today?

One share of BNR stock can currently be purchased for approximately $21.48.

How big of a company is Legend Biotech?

Legend Biotech has a market capitalization of $2.19 billion. Legend Biotech employs 753 workers across the globe.

What is Legend Biotech's official website?

The official website for Legend Biotech is www.brbiotech.com.

How can I contact Legend Biotech?

The company can be reached via phone at 86 20 3403 7871.

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.